Nanotherapy used to further advance Type 1 Diabetes vaccine

Nanotherapy used to further advanced Type 1 Diabetes vaccine
Nanotherapy used to further advanced Type 1 Diabetes vaccine | Courtesy of

A recent article described a new step forward in developing a vaccine to prevent Type 1 Diabetes onset, using nanotherapy technology.

Two years earlier, researchers at the Immunology of Diabetes Research Group at the Germans Trias Research Institute discovered a new, experimental immunotherapy that could prevent Type 1 Diabetes in mice that showed a predisposition to Type 1 Diabetes.

Thanks to additional studies and support from the Catalan government and the Spanish government, as well as private patrons, further discoveries have shown that there may be a vaccine that can not only prevent but cure Type 2 Diabetes.

The researchers made nanoparticles known as liposomes in their laboratory and then introduced the liposomes into a subject’s body. These liposomes stop beta cells from destructing, which helps to prevent Type 1 Diabetes from developing.

Now that scientists have demonstrated that the liposomes can prevent Type 1 Diabetes from onsetting in mice subjects, they can test the treatment on human cells in vitro and eventually launch clinical trials with human test subjects.

This new method could be an ideal candidate for a new human vaccine to prevent or cure Type 1 Diabetes.

Further details are available online in PLOS ONE.

Organizations in this Story


Want to get notified whenever we write about PLOS ONE ?
Next time we write about PLOS ONE, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.